Table 3.

Metastatic tumor signature subtype split by relapse site (N = 109)

Signature	Lymph node 40 (37%)	Relapse site N (%)
		Other sites (combined) 69 (63%)	Liver 26 (24%)	Skin 20 (18%)	Breast 15 (14%)	Skeleton 5 (4%)	Lung/Pleura 2 (2%)	Other 1 (1%)	Pa
Genomic grade
GG1	6 (15)	23 (33)	13 (50)	4 (20)	4 (27)	1 (20)	0 (0)	1 (100)
GG3	34 (85)	46 (67)	13 (50)	16 (80)	11 (73)	4 (80)	2 (100)	0 (0)	0.062
70 gene
Low	5 (12)	18 (26)	10 (38)	2 (10)	3 (20)	1 (20)	1 (50)	1 (100)
High	35 (88)	31 (74)	16 (62)	18 (90)	12 (80)	4 (80)	1 (50)	0 (0)	0.152
Recurrence score
Low	1 (2)	2 (3)	1 (4)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)
Intermediate	2 (5)	4 (6)	1 (4)	2 (10)	1 (7)	0 (0)	0 (0)	0 (0)
High	37 (93)	63 (91)	24 (92)	17 (85)	14 (93)	5 (100)	2 (100)	1 (100)	1.000b
CCS
Low	3 (8)	6 (9)	3 (11)	3 (15)	0 (0)	0 (0)	0 (0)	0 (0)
Intermediate	3 (8)	15 (22)	7 (27)	2 (10)	5 (33)	0 (0)	0 (0)	1 (100)
High	34 (84)	48 (69)	16 (62)	15 (77)	10 (67)	5 (100)	2 (100)	0 (0)	0.107b
ROR-Sc
Low	1 (2)	3 (4)	1 (4)	1 (6)	1 (7)	0 (0)	0 (0)	0 (0)
Medium	8 (20)	31 (48)	18 (69)	5 (29)	5 (33)	2 (40)	1 (50)	0 (0)
High	31 (78)	31 (48)	7 (27)	11 (65)	9 (60)	3 (60)	1 (50)	0 (0)	0.006b
PAM50c
Luminal A	2 (5)	9 (14)	6 (23)	1 (6)	2 (13)	0 (0)	0 (0)	0 (0)
Luminal B	11 (28)	23 (35)	12 (46)	3 (18)	4 (27)	3 (60)	1 (50)	0 (0)
HER2-enriched	12 (30)	20 (31)	8 (31)	4 (23)	6 (40)	2 (40)	0 (0)	0 (0)
Basal-like	15 (37)	13 (20)	0 (0)	9 (53)	3 (20)	0 (0)	1 (50)	0 (0)	0.177b

NOTE: Bold values indicate P < 0.05.

^aP values are based on the χ² or Fisher exact test comparison of lymph node versus other sites combined columns.

^bThe Fisher exact test.

^cReduced numbers (n = 105).